Intellia Therapeutics, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 132.16 million compared to USD 113.41 million a year ago. Basic loss per share from continuing operations was USD 1.46 compared to USD 1.4 a year ago.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.62 USD | -1.02% | -0.37% | -15.93% |
May. 09 | Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises | MT |
May. 09 | Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.91% | 2.5B | |
+41.97% | 54.04B | |
+43.57% | 41.96B | |
-1.20% | 41.92B | |
-7.59% | 28.35B | |
+12.16% | 26.35B | |
-22.69% | 19B | |
+7.81% | 13B | |
+28.70% | 12.28B | |
+25.41% | 12.19B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023